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  Abstract 1 
Characterising the protein signatures in tumours following vascular-targeted therapy will help 2 
determine both treatment response and resistance mechanisms. Here, mass spectrometry 3 
imaging and MS/MS with and without ion mobility separation have been used for this 4 
purpose in a mouse fibrosarcoma model following treatment with the tubulin-binding tumour 5 
vascular disrupting agent, combretastatin A-4-phosphate (CA-4-P).  Characterisation of 6 
peptides after in-situ tissue tryptic digestion was carried out using Matrix Assisted Laser 7 
Desorption Ionisation- Mass   Spectrometry (MALDI-MS) and Matrix Assisted Laser 8 
Desorption Ionisation- Ion Mobility Separation- Mass  Spectrometry Imaging (MALDI-IMS-9 
MSI) to observe spatial distribution of peptides. Matrix Assisted Laser Desorption Ionisation- 10 
Ion Mobility Separation- Tandem Mass Spectrometry (MALDI-IMS-MS/MS) of peaks was 11 
performed to elucidate any pharmacological responses and potential biomarkers.  By taking 12 
tumour samples at a number of time points after treatment gross changes in the tissue were 13 
indicated by the changes in the signal levels of certain peptides. These were identified as 14 
arising from haemoglobin and indicated the disruption of the tumour vasculature.  It was 15 
hoped that the use of PCA-DA would reveal more subtle changes taking place in the tumour 16 
samples however these are masked by the dominance of the changes in the haemoglobin 17 
signals. 18 
 19 
 20 
21 
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 1 
Introduction 2 
The discovery of biomarkers that can be used to determine success of cancer therapy or 3 
resistance to it, at an early stage, presents a very complex problem. There are countless 4 
biochemical pathways to be considered and the multifaceted characteristics of the cancer 5 
cell have also to be taken into account; a cell that can largely evade the host’s immune 6 
responses and has mastered tissue invasion and anti-cancer drug resistance. Nevertheless 7 
good places to start are the ‘Hallmarks’ of cancer proposed by Hanahan and Weinburg 8 
(2000), these include; evasion of apoptosis, self-sufficiency in growth signals, insensitivity to 9 
anti-growth signals, tissue invasion and metastasis, limitless replicative potential and 10 
sustained angiogenesis. [1]. These capabilities have been used by Lord and Ashworth to 11 
classify current anti-cancer drugs [2]. One key point raised in this article is that to decipher 12 
the mechanisms of cancer, it should be borne in mind how drugs disturb whole biochemical 13 
networks as opposed to solitary pathways.  They called this concept, “drugging the 14 
undruggable”. 15 
One promising class of anti-cancer drug currently under development are vascular disrupting 16 
agents (VDAs) [3]. VDAs cause rapid, selective and sustained shutdown of tumour blood 17 
flow, which produces drastic effects on the tumour microenvironment. At least part of the 18 
blood flow effects are due to direct effects on endothelial cells that line the luminal surface of 19 
blood vessels. The article by Kanthou and Tozer [3] describes a proposed mechanism of 20 
action for CA-4-P. It is suggested that increased permeability after the administration of CA-21 
4-P is one major factor in the disruption of endothelial organisation. Interference in vascular 22 
integrity due to abnormality in the cytoskeleton, subsequently leads to stress fibre formation 23 
and endothelial cells become more rounded (‘blebbing’). Haemorrhagic necrosis follows, 24 
exacerbating the already hypoxic regions within the tumour microenvironment. Remodelling 25 
and formation of actin stress fibres is clearly shown in immunofluorescence work by 26 
Siemann (2011). The images contained in this article are good examples of the “rounding” of 27 
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endothelial cells and “condensation” of the microtubules post CA-4-P treatment. Drug 1 
delivery of VDAs is relatively simple due to endothelial positioning near the bloodstream and 2 
the diploid target cells are thought not to be directly drug resistant due to low risk of 3 
mutations. VDAs have relatively good clinical measurability i.e. blood flow and in most cases 4 
short-term exposure of a VDA creates sufficient hypoxic conditions to induce necrosis.  5 
However, the use of VDAs to increase hypoxia can also have undesirable consequences 6 
[5,6].  Hypoxia-inducible factors (HIF), which are prevalent under hypoxic conditions, cause 7 
up-regulation of pro-angiogenic factors such as VEGF. So could VDA amplify the angiogenic 8 
process after the creation of an increased hypoxic tumour environment? Hypothetically 9 
speaking this could even help the metastatic process ensuring tumour invasion [5] 10 
In addtion to acquired resistance to treatment, the heterogeneous tumour mass could well 11 
contain a cell population oblivious to vascular targeted strategies, representing innate 12 
resistance [4]. This is supported by the hypothesis that there are four possible micro-13 
vascular phenotypes in existence; normal pre-existing, tumour phenotypic vessels, normal 14 
neo-vasculature and abnormal (pathological) neo-vasculature.  This could explain why some 15 
tumour regions remain unaffected by VDA treatment, including the well-documented viable 16 
tumour rim [7]. The viable tumour rim is also thought to achieve evasion through its 17 
positioning, adjacent to the non-diseased tissue, which is well supplied with oxygen and 18 
essential nutrients [8].   19 
Resistance mechanisms against VDAs are clearly complex and multi-factorial but increased 20 
knowledge in this area could provide strategies for future combination therapies. The largest 21 
group of VDAs are tubulin binding, microtubule-depolymerising drug such as combretastatin 22 
A-4-3-O-phosphate (CA-4-P/ ZybrestatTM), which is currently in late stage clinical trials.  23 
Combination of CA-4-P or a related compound, Oxi4503 (CA-1-P), with anti-angiogenic 24 
therapy such as VEGF receptor tyrosine kinase inhibitors has already shown promise and 25 
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novel concepts aimed at targeting circulating angiogenic endothelial progenitor cells have 1 
also been proposed. This area has been recently reviewed by Siemann [9] 2 
MALDI-MSI is an advanced analytical tool that allows molecular profiling and imaging of 3 
many classes of compounds including; proteins, peptides, lipids, drugs and many other 4 
molecules directly from tissue sections.  The use of this technique for the study of biological 5 
tissue was first described by Caprioli et al. in 1997 [10] and it has been improved and 6 
adapted for use in many other studies [11-17].  Briefly MALDI-MSI allows the acquisition of 7 
multiple single mass spectra across the tissue section at a spatial resolution predefined by 8 
the operator (typically 20-200m). These mass spectra are then combined together in order 9 
to generate molecular maps or images which represent the distribution and the relative 10 
abundance and/or intensity of a specific ion signal detected within the tissue section.  11 
MALDI-MSI has been shown to be a powerful technique for direct protein analysis within 12 
tissue sections and in tumour tissue samples, it has been used for discrimination between 13 
tumour and non tumour regions with no requirement for predefined targets [18-21].  A recent 14 
and exciting development in the technique is the use of "on-tissue" tryptic digestion in order 15 
to achieve direct identification of proteins within a tissue section [22-24].  16 
Such molecular profiling and imaging could be described as a bottom-up shotgun approach 17 
to protein identification, performed directly on cryo-sectioned tissue samples, rather than 18 
through protein extraction methods. The chance to visualise the positioning of peptides 19 
within an image generated by MALDI-MSI could indeed advance our knowledge in cancer 20 
research studies. Also being able to observe co-localisation of peptides and possibly relate 21 
them to disease states can provide complementary information regarding cancerous tissues. 22 
A 2009 article by Djidja et al [25] described the profiling and imaging of glucose-regulated 23 
protein 78 kDa (Grp78) in pancreatic tumour sections and contains a clear example of 24 
peptide identification from the peptide mass fingerprint (PMF) of a tryptic digest. Here in-situ 25 
tryptic digestion was performed directly onto tissue sections, the resulting PMF allowed 26 
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selection of precursor ion for MS/MS. As described within the article, the MALDI images 1 
were the first of their kind, with the discussion emphasising the low abundance of this 2 
particular heat shock protein.  However its importance is not to be underestimated in the 3 
aggressiveness, progression and drug resistant nature of tumours. The paper then goes on 4 
to describe how the combination of ion mobility and MALDI helped to selectively target 5 
specific proteins for imaging. This technique has been called matrix assisted laser 6 
desorption ionisation ion mobility separation mass spectrometry imaging (MALDI-IMS-MSI) 7 
and its advantages for specific imaging of specific proteins has also been described by 8 
others [26]. 9 
 10 
The experimental work reported here, describes a study, by MALDI-MSI and MALDI-IMS-11 
MSI, of the proteins induced in a mouse transplanted fibrosarcoma model (VEGF120 12 
tumours), at a number of time points, following treatment with CA-4-P.  Imaging of peptides 13 
signals after in-situ tissue tryptic digestion was carried out using MALDI-MS and MALDI-14 
IMS-MSI to observe their spatial distribution. MALDI-IMS-MS/MS of the peptide signals was 15 
performed to identify proteins involved in the pharmacodynamic responses to treatment. 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
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Materials and Methods 1 
Materials- 2 
α  – Cyano-4-hydroxycinnamic acid CHCA, aniline (ANI), ethanol (EtOH), chloroform 3 
(CHCl3), acetonitrile (ACN), Octyl-α / β -glucoside (OcGlc), Tri-fluoroacetic acid (TFA), 4 
ammonium calcium carbonate, Haematoxylin, eosin, xylene, DPX mountant were from 5 
Sigma-Aldrich (Dorset, UK). Modified sequence-grade trypsin (20µg lyophilised) was 6 
obtained from Promega (Southampton, UK). 7 
 8 
Tissue samples- 9 
Mice were injected sub-cutaneously in the flank with a 50l tumour cell suspension 10 
containing 1x106 cells in serum-free medium. The cells employed in this study were from the 11 
mouse fibrosarcoma cell line, VEGF120. This has been engineered to express only the 12 
VEGF120 isoform [27].  Tumours were allowed to grow to approximately 500mm3, before 13 
CA-4-P treatment (a single dose of 100mg/kg i.p). Mice were killed and tumours excised at 14 
various time after treatment. 15 
Experimental groups: 16 
Controls (no treatment), n=6 (labelled tumour 1_1 - tumour 1_6), C-A4-P (0 hours after 17 
treatment), n=6, (labelled tumour 2_1 - tumour 2_6), , C-A4-P (1/2 hour after treatment), n=6, 18 
(labelled tumour 3_1 - tumour 3_6), C-A4-P (6 hours after treatment), n=6, (labelled tumour 19 
4_1 - tumour 4_6), C-A4-P (24 hours after treatment) n=6, (labelled tumour 5_1 - tumour 5_6) 20 
 21 
Tissue preparation - 22 
Frozen tissue sections were cut to ~10µm, sections using a Leica CM3050 cryostat (Leica 23 
Microsystems). The sections were then freeze thaw mounted on poly-lysine glass slides. 24 
Page | 9 
 
Mounted slides were either used immediately or stored in an airtight tube @ -80°C for 1 
subsequent use. 2 
In situ tissue digestion - 3 
The tissue samples were washed initially with 70% and 90% ethanol respectively for 1 4 
minute then left to dry, after slides were immersed in Chloroform for 10 seconds. Prior to 5 
matrix application In situ tissue digestion was performed with trypsin solution prepared (from 6 
lyophilised trypsin) at 20µg/ml by addition of 50mM ammonium bicarbonate (NH4HC03) pH 7 
8.12, containing 0.5% Octyl-α/ β-glucoside (OcGlc). Two automated systems were used 8 
for trypsin application.  The "Suncollect" (SunChrom, Friedrichsdorf, Germany) automatic 9 
pneumatic sprayer was used to spray trypsin in a series of 5 layers employing flow rates of 10 
2µl/min, 3µl/min and 4µl/min. The PortraitTM 630 Multispotter (Labcyte, Sunnyville CA) was 11 
used to apply trypsin in a 200 µm - 300 µm array of spots. The sections for MALDI-MS and 12 
MALDI-MSI were incubated in a humidity chamber containing H20 50%: Methanol 50% 13 
overnight @ 37°C/ 5% C02. 14 
Matrix deposition – 15 
The matrix α-cyano-4-hydrocinnamic acid (CHCA) 5mg/ml (Suncollect) or 10mg/ml 16 
PortraitTM ) and aniline  in acetonitrile: water: TFA (1:1:0.1) was applied using the Suncollect 17 
and PortraitTM 630 Multispotter as above with identical coordinate settings to trypsin 18 
deposition to ensure conformity. Aniline was added to the CHCA solution in equimolar 19 
amounts to the CHCA added (i.e. 5mg/ml CHCA matrix solution will contain 2.4µl 20 
aniline). 21 
Instrumentation - 22 
Peptide mass fingerprints and images were acquired by MALDI-MS/MSI using an Applied 23 
Biosystems Q-Star Pulsar i hybrid quadrupole time-of-flight mass spectrometer fitted with a 24 
variable repetition rate Nd:YV04  laser set at 5 kHz . Image acquisition was performed using 25 
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raster imaging mode at 150µm spatial resolution, Biomap 3.7.5.5 software was used for 1 
image generation. To enable simple visual comparison between images all data was 2 
normalised to m/z 877 (a peak arising from theCHCA matrix.) and intensity scales in the 3 
BioMap software were all set to the same value.  4 
 5 
MALDI-IMS/MS, MALDI-IMS/MSI and MALDI-IMS/MS/MS were performed using a HDMS 6 
SYNAPT ™ G2 system (Waters  Corporation, Manchester, UK). Drift scope 2.1 software 7 
(Waters Corporation, UK.  In order to achieve good quality MS/MS spectra, they were 8 
acquired manually moving the laser position and adjusting the collision energy to achieve 9 
good signal to noise for product ions across the full m/z range of the spectrum. Collision 10 
energies were adjusted from 70 – 100 during acquisition and acquisition times were 11 
generally of the order of 5-10 seconds per spectrum. 12 
Haematoxylin and eosin staining – 13 
Slides were immersed in Haematoxylin for 1 minute, rinsed in tap water until water runs clear, 14 
immerse in 1% Eosin for 30 seconds, rinsed in tap water until water runs clear, dehydration: 15 
50% ethanol for 2min, 70% ethanol for 2 min, 80% ethanol for 2 min, 95% ethanol for 2 min, 16 
4 changes of Xylene applied to each slide for 1 min at a time, mounted with DPX mountant 17 
and left to dry in the fumehood overnight. 18 
Data pre-processing 19 
Data lists were exported from Analyst QS software as text files then imported into to 20 
SpecAlign to undergo the following data processing; baseline 5, baseline subtraction, 21 
smooth, denoise, normalise TIC, remove negative, generate average spectrum, processing 22 
spectral alignment, PAFFT correlation method max shift 20. Files were then exported as 23 
separate csv. Files and finally exported as text files to import into Marker View software. 24 
Statistical Analysis 25 
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PCA-DA was performed using Marker View software, post SpecAlign text files were imported 1 
and data was transposed into table format. Minimum intensity 0.1 was selected with 2 
maximum number of peaks 20,000. Monoisotopic peaks selected by Marker View were used 3 
in the supervised PCA-DA. 4 
 5 
Results 6 
 A representative peptide mass fingerprint obtained from a tumour from an animal sacrificed 7 
immediately after administration of CA-4-P (herafter referred to 0 hours CA-4-P) obtained on 8 
the Synapt instrument is shown in Figure 1. These data provide illustration of the vast 9 
number of peptides that arise from an in-situ tissue tryptic digest, as previously reported by 10 
ourselves and others [21-24]. Figure 2 shows IMS/MS/MS data obtained from the peak at 11 
m/z 1819.8. This was identified by MASCOT search as arising from Mouse HbA  42-57 12 
(TYFPHFDVSHGSAQVK ) (Table 1). These data (Figure 2 b and 2c) are also a further 13 
indication of the advantages of IMS for the identification of "on-tissue" generated tryptic 14 
peptides. The complexity of the obtained data sets is shown in Figure 2b, where ions arising 15 
from doubly charged species and singly charged species are clearly separated by the use of 16 
ion mobility and further those singly charged ions arising from peptides and matrix adducts 17 
and lipids are also separated. The use of IMS separation prior to MS/MS yielded good 18 
quality MS/MS spectra for peptides  that produced a high and significant MASCOT score. 19 
 20 
Figure 3 (a-e) shows peptide mass fingerprints obtained from the MEF120 tumour tissue 21 
sections treated with saline/ CA-4-P in the time course experiments (these data were 22 
obtained using the Q-Star instrument).  Figure 3a (a) Control/ saline, (b) 0 hours post CA-4-P, 23 
(c) 0.5 hours post CA-4-P, (d) 6 hours post CA-4-P, and (e) 24 hours post CA-4-P. The 24 
increase in the relative intensity of m/z 1819.3 along with other readily identifiable 25 
haemoglobin peptides (e.g. m/z 1529.7 HbA 18-32 (IGGHGAEYGAEALER), m/z 1274.3 26 
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HbA 52-41 (LLVVPWTQR) can be clearly seen. This increase in tissue haemoglobin is as 1 
would be expected considering the vascular damaging properties of CA-4-P. Due to 2 
disruption of the 3D capillary architecture, endothelial cell necrosis, leakage of blood cells 3 
into tumour tissues is inevitable.  It is clearly illustrated by Figure 4, where MALDI-MS 4 
images for the distribution on m/z 1274 (HbA 52-41) at each time point are shown along 5 
with photographs of the corresponding haematoxylin and eosin stained sections.   6 
 7 
The haematoxylin and eosin staining of each VEGF120 serial section was performed after 8 
imaging for identification of viable and necrotic tissue and to make observations of the 9 
tumour rim. Examples of viable and necrotic tissue are shown in Figure 5. (a) shows a 10 
control saline-treated tumour , which is essentially viable, (b) shows a control tumour with a 11 
small necrotic region, (c) 0 hours CA-4-P showing viable tissue, (d) 0 hours CA-4-P showing 12 
viable and necrotic regions, (e) 0.5 hours after CA-4-P showing viable tissue, (f) 0.5 hours 13 
after CA-4-P showing viable and increasing necrotic regions, (g) 6 hours after CA-4-P 14 
showing partially viable regions, (h) 6 hours after CA-4-P with haemorrhage and necrosis, (i) 15 
24 hours after CA-4-P treatment showing total necrosis. 16 
 17 
Higher magnification images of the H&E staining of tumour rim in the VEGF120 tumour 18 
sections are shown in Figure 6 (a) Control/ saline, (b) 0 hours CA-4-P, (c) 0.5 hours CA-4-P, 19 
(d) 6 hours CA-4-P, and (e) 24 hours CA-4-P. The H&E tissue sections above reflect the 20 
heterogeneous nature of the tumour especially considering the control with no CA-4-P, 21 
however the effect of the vascular disrupting agent is still apparent and the 0.5 hour image 22 
suggests a good example of the viable tumour resistant rim. In all images viable tumour cells 23 
have densely packed nuclei which appear as regions or "organised cells" which stain blue in 24 
H&E staining whereas regions of necrosis, due to cell lysis tend to show as a disorganised 25 
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region with less blue staining. In these data haemorrhaging  also gives a pink colour to the 1 
tissue e.g. Fig 5h" 2 
 3 
Principle component analysis – discriminant analysis (PCA-DA) was performed to try and 4 
correlate peptide induction with dose response and to provide a method of further analysing 5 
the PMF data.  Figure 7 shows the results of PCA-DA of VEGF120 In-situ tryptic digests.  6 
7(a): the scores plot showing groupings and variability between tumour time point spectra, 7 
(b): the loadings plot displays the separation and spatial distribution of m/z values in relation 8 
to score plot positions, (c): illustrates the variability of two haemoglobin peptides within each 9 
tumour section The red arrow on Figure 7(b) indicates m/z 1274 (indicative of haemoglobin 10 
β chain) which is associated with the tumour 4 set (6 hours CA-4-P).  In Figure 7(b) the 11 
green data points are peaks identified as monoisotopic by the MarkerView software and blue 12 
data points are peaks which have not been assigned as monoisotopic, these are termed 13 
"default" by the software.  14 
 15 
The MALDI-MSI images shown in Figure 8 show the distribution of two known peptides in 16 
tumour 5_6 i.e. a tumour 24hours after treatment with CA-4-P (a) m/z 1416 from 17 
Haemoglobin α  chain depicting central necrotic haemorrhage and (b) m/z 1198 18 
corresponding to Actin. The inverse nature of their distribution is striking. 19 
 20 
Figure 9 shows examples of overlaid images to show differing spatial distribution and co-21 
registration of peptides using MALDI-MSI. (a) m/z 944 Histone 2A in red (from rainbow) and 22 
m/z 1274 Hb in solid green, (b) m/z 1819 Hb in red (from rainbow) and m/z 944 Histone 2A 23 
in solid green.   The MASCOT scores for the IMS/MS/MS analyses of these peptides are 24 
given in Table 1. 25 
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 1 
Discussion 2 
The potential for investigations into protein induction following drug treatment strategies are 3 
phenomenal. Currently one major challenge is the management and analysis of the large 4 
amounts of data generated.  In each of the peptide mass fingerprints (Figures 1 and 3), on 5 
first inspection the spectrum seemed to be very noisy however this could be a signature of a 6 
successful tryptic digestion. Therefore the many low abundance peptide signals contained in 7 
the apparent noise could house significant proteins such as heat shock proteins and the like, 8 
in addition of to the expected and readily visible abundant peptide signals (actin, histones 9 
etc).  Due to the nature of these results one has to question whether or not each peak is 10 
worthy of further scrutiny, or should the vast amount of peaks be simply treated as noise/ 11 
interference. The use of ion mobility separation and its associated data extraction software 12 
certainly appears to ease this dilemma making many more signals visible for subsequent 13 
examination by MS/MS. 14 
In this work the suspected pharmacological response to treatment with CA-4-P of 15 
haemorrhaging was investigated (Figure 6). The MALDI-MS images generated from 16 
m/z1274 in Figure 4 show a clear increase in Hb with time after treatment with CA-4P.  The 17 
latter is then confirmed in Figure 5 in the H&E sections. At 6 hours after CA-4-P treatment, 18 
the tumour in Figure 5 was partially necrotic and Hb was evident in both necrotic & viable 19 
tumour regions. The tumour excised at 24 h was almost completely necrotic. The increase in 20 
haemoglobin is also clearly visible in Figure 7(c), the time course plot extracted from the 21 
PCA-DA data, where again the increase in m/z 1274 and m/z 1820 can be clearly observed. 22 
Many other peptides were observed in this work, including some tentatively identified as 23 
arising from VEGF isoforms other than VEGF120. This may be due to infiltration of immune 24 
cells [26].This influx and subsequent induction of certain chemokines is a studied response 25 
to tumour vascular targeted therapy. In MALDI-MS/MS investigations (results not shown) a 26 
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peak at m/z 1334 could indicate Interleukin-6 precursor (IL-6), which has been reported to be 1 
induced in tumours after an anti-tumour agent [27], further IMS/MS/MS experiments are 2 
required to confirm this.  3 
In PCA-DA analysis of complex data sets, the scores plot (in this case Figure 7a) represents 4 
the variance of the original variables, i.e. the obtained sample groups.  The loadings plot (in 5 
this case Figure 7b) describes the variable behaviour and differences between the observed 6 
groups. The PCA-DA analysis of tryptic digest spectra from VEGF120 tumour tissue 7 
reported here shows good grouping of the tumour time points (Figure 7a). Confirmation of  8 
the increase in haemoglobin due to CA-4-P treatment is given by the association of 9 
heamoglobin ions with the 24hr tumour in the loadings plot (Figure 7b) and this is futher 10 
shown in Figure 7(c). Further analysis of this large data set is currently underway.  The aim 11 
of this is to examine whether changes in signals arising from proteins of lower abundance 12 
will provide an insight into other pharmacodynamic responses to the treatment.  13 
  14 
Conclusions 15 
 MALDI-MSI has been used to study the effect of treatment with CA-4-P, a vascular 16 
disrupting agent in late stage clinical trials, on mouse VEGF120 tumours.  A strategy 17 
incorporating "on-tissue" tryptic digestion, MS/MS to identify peptides and ion mobility 18 
separation to improve specificity was employed.  By taking tumour samples at a number of 19 
time points after treatment, gross effects were clearly visible by changes in the expression of 20 
certain peptides. These were identified as arising from haemoglobin and indicated the 21 
disruption of the tumour vasculature.  It was hoped that the use of PCA-DA would reveal 22 
more subtle changes taking place in the tumour samples however at present these are 23 
masked by the dominance of the changes in the haemoglobin signals. Further statistical 24 
analysis of these data is in progress to see if this can be resolved. 25 
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 1 
 2 
Table 1: Identities and MASCOT scores from the IMS/MS/MS analyses of the peptide 3 
signals imaged. 4 
 5 
Protein Accession 
number 
Observed 
m/z with 
MALDI-MSI 
Sequence Score MASCOT 
threshold 
score at 95% 
significance 
Haemoglobin 
subunit alpha 
P01942 2836.4 VADALASAAGHLDDLPGALSALSDLHAHK 87 >40 
Haemoglobin 
alpha chain 
P01942 1819.8 TYFPHFDVSHGSAQVK 106 >36 
Haemoglobin 
alpha chain 
P01942? 1416.7 GGHGAEYGAEALER 87 >43 
Haemoglobin 
beta chain 
P02088 1302.6 VNSDEVGGEALGR 79 >38 
Histone H3 P68433 1032.6 YRPGTVALR 11 >10 
Histone 2A Q8CGP5 944.5 AGLQFPVGR 24 >19 
 6 
 7 
 8 
 9 
 10 
11 
Page | 21 
 
 1 
Legends to Figures 2 
 3 
Figure 1:  Representative Peptide Mass Fingerprint (PMF) arising from an on-tissue digest 4 
of a VEGF120 tumour 0 hours after dosing with 100mg/kg i.p, CA-4-P. Prior to matrix 5 
application In situ tissue digestion was performed with trypsin solution prepared (from 6 
lyophilised trypsin) at 20µg/ml by addition of 50mM ammonium calcium carbonate 7 
(NH4CaC03) pH 8.12, containing 0.5% Octyl-α/ β-glucoside (OcGlc).  The matrix employed 8 
was α-cyano-4-hydroxycinnamic acid (CHCA) 5mg/ml and aniline in acetonitrile: water: TFA 9 
(1:1:0.1).  10 
 11 
Figure 2a: IMS/MS/MS data obtained from the peak observed in Figure 1 at m/z 1819.3. 12 
This was identified by MASCOT search as arising from Mouse HbA  42-57 13 
(TYFPHFDVSHGSAQVK ). 14 
 15 
Figure 2b: A Driftscope plot of a tumour section 24 hrs post CA-4-P showing the ion 16 
mobility separation as a function of driftime. Possible trend lines of doubly charged 17 
singly charged and suspected matrix adduct ions/ lipids are indicated.  18 
 19 
Figure 2c: Zoomed in Driftscope plot shows ion mobility separation of ion of interest 20 
Haemoglobin subunit alpha m/z 1819.8 and C13 as shown on chromatogram directly 21 
below. 22 
 23 
Figure3: Peptide mass fingerprints obtained from the VEGF120 tumour tissue sections 24 
treated with saline/ 100mg/kg i.p, CA-4-P time course experiments.  Figure 3a (a) Control/ 25 
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saline, (b) 0 hours post CA-4-P,(c) 0.5 hours post CA-4-P, (d) 6 hours post CA-4-P, (e) 24 1 
hours post CA-4-P.  2 
 3 
Figure 4: MALDI-MS images for the distribution of m/z 1274 (HbA 52-41) at (a)Control/ 4 
saline, (b) 0 hours post CA-4-P (c) 0.5 hours post CA-4-P, (d) 6 hours post CA-4-P, (e) 24 5 
hours post CA-4-P along with photographs of the corresponding haematoxylin and eosin 6 
stained sections. 7 
 8 
Figure 5: Haematoxylin and eosin stained sections (a) Control/ saline showing viable tissue, 9 
(b) Control showing, a small necrotic region, (c) 0 hours CA-4-P showing viable tissue, (d) 0 10 
hours CA-4-P showing viable and necrotic regions, (e) 0.5 hours CA-4-P showing viable 11 
tissue, (f) 0.5 hours showing viable and increasing necrotic regions, (g) 6 hours CA-4-P 12 
showing partially viable regions, (h) 6 hours CA-4-P with haemorrhaging and necrosis, (i) 24 13 
hours after CA-4-P treatment showing total necrosis. 14 
 15 
Figure 6: Higher magnification images of the H&E staining of tumour rim in the VEGF120 16 
tumour sections are shown in Figure 6 (a) Control/ saline, (b) 0 hours CA-4-P, (c) 0.5 hours 17 
CA-4-P, (d) 6 hours CA-4-P, (e) 24 hours CA-4-P. The 0.5 hour image displays a good 18 
example of the viable tumour resistant rim. 19 
 20 
Figure 7: PCA-DA of VEGF120 tumour In-situ tryptic digests.  (a): the scores plot showing 21 
groupings and variability between tumour time point spectra, (b): the loadings plot displaying 22 
the separation and spatial distribution of m/z values in relation to score plot positions, (c): 23 
illustrates the variability of two haemoglobin peptides within each tumour section The red 24 
arrow on Figure 7(b) indicates m/z 1274 (indicative of haemoglobin β  chain) which is 25 
associated with the tumour 4 set (6 hours CA-4-P).  26 
 27 
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Figure 8: The distribution of two known peptides in tumour 5_6 i.e. a tumour 24hours after 1 
treatment with CA-4-P (a) m/z 1416 from Haemoglobin α chain depicting central necrotic 2 
haemorrhage and (b) m/z 1198 corresponding to Actin. The inverse nature of their 3 
distribution is striking. 4 
 5 
Figure 9: Overlaid MALDI-MSI images showing differing spatial distribution and co-6 
registration of peptides. (a) m/z 944 Histone 2A in red  and m/z 1274 Hb in solid green, (b) 7 
m/z 1819 Hb in red and m/z 944 Histone 2A in solid green. 8 
 9 
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Figure 3d 1 
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Figure 3e 1 
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